Literature DB >> 27728

Substance P: binding to lipids in the brain.

F Lembeck, N Mayer, G Schindler.   

Abstract

1. Substance P (SP) could be extracted from brain homogenates with chloroform-methanol by a method which extracts all lipids. 2. SP could be transferred form this total lipid extract (TLE) into an aqueous solution at low pH values (2.0--3.0). 3. At higher pH values (5.5) SP could be transferred from an aqueous phase into an organic phase (chloroform:methanol, 2:1) and recombined with TLE (which was previously freed from endogenous SP) contained in this phase. The binding capacity of TLE for SP exceeded by far the amount of endogenous SP bound originally in the brain extracts. 4. Among the lipids present in TLE, phosphatidylserine was able to bind and release SP in a pH dependent manner. 5. It is suggested that SP bound to phosphatidylserine is the storage form of SP in the brain. The mechanisms by which it is released are still unknown. The possibility that the SP-receptor is also a phospholipid is considered.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 27728     DOI: 10.1007/BF00496188

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  12 in total

1.  A simple method for the isolation and purification of total lipides from animal tissues.

Authors:  J FOLCH; M LEES; G H SLOANE STANLEY
Journal:  J Biol Chem       Date:  1957-05       Impact factor: 5.157

2.  [Enzymatic degradation of substance P].

Authors:  O EBER; F LEMBECK
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1956

3.  The preparation and characterization of synaptic vesicles of high purity.

Authors:  A Nagy; R R Baker; S J Morris; V P Whittaker
Journal:  Brain Res       Date:  1976-06-11       Impact factor: 3.252

4.  [Substance P and salivary secretion].

Authors:  F Lembeck; K Starke
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1968

5.  [Obtaining substance P from the lipid extract of brain tissue].

Authors:  A Heizmann; F Lembeck; G Seidel
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1966

6.  Differentiation of substance P and physalaemin.

Authors:  F Geipert; F Lembeck
Journal:  Naunyn Schmiedebergs Arch Pharmakol       Date:  1969

7.  Fractionation of lipids and proteolipids from cat grey white matter by chromatography on an organophilic dextran gel.

Authors:  E F Soto; J M Pasquini; R Plácido; J L La Torre
Journal:  J Chromatogr       Date:  1969-05-20

8.  Ultrastructural localization of substance P in neurons of rat spinal cord.

Authors:  V M Pickel; D J Reis; S E Leeman
Journal:  Brain Res       Date:  1977-02-25       Impact factor: 3.252

9.  Substance P: localization in synaptic vesicles in rat central nervous system.

Authors:  A C Cuello; T M Jessell; I Kanazawa; L L Iversen
Journal:  J Neurochem       Date:  1977-10       Impact factor: 5.372

10.  Hypothalamic substance P as a candidate for transmitter of primary afferent neurons.

Authors:  M Otsuka; S Konishi; T Takahashi
Journal:  Fed Proc       Date:  1975-09
View more
  4 in total

1.  Substance P: model studies of its binding to phospholipids.

Authors:  F Lembeck; A Saria; N Mayer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-04       Impact factor: 3.000

2.  Substance P: characteristics of binding to synaptic vesicles of rat brain.

Authors:  N Mayer; F Lembeck; A Saria; R Gamse
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-01       Impact factor: 3.000

3.  Further characterization of the binding of substance P to a fraction from rabbit brain enriched in synaptic membranes.

Authors:  Y Nakata; Y Kusaka; H Yajima; K Kitagawa; T Segawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-11       Impact factor: 3.000

4.  Regional distribution and biochemical properties of 125I-Tyr8-substance P binding sites in synaptic vesicles.

Authors:  A Saria; N Mayer; F Lembeck; M Pabst
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-03       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.